Cold-chain shipping for GLP-1 and peptide brands: who pays when it fails

Pharmacies describe GLP-1 cold chain shipping as a logistics problem and patients describe it as a trust problem. For the brand that sits between them it is a retention and refund problem first. A box that arrives warm on a Saturday afternoon, gel packs soft and vial at room temperature, produces a support ticket, a replacement shipment, a missed dose, and a patient who now doubts the product. The pharmacy sees one failed parcel. The brand sees a member whose next renewal is in question. Who pays for the replacement is decided in the pharmacy agreement, and operators who never read that clause discover it during the first hot week of summer.

Why temperature matters for these products

Semaglutide, tirzepatide and most therapeutic peptides are peptide chains in solution. Heat degrades them, freezing damages them, and light does neither any good. The approved label is the clearest public statement of the tolerance. Section 16 of the Wegovy prescribing information says to store the single-dose pen or syringe in the refrigerator at 2 to 8 degrees Celsius, which is 36 to 46 degrees Fahrenheit; that before the cap is removed the pen may be kept at 8 to 30 degrees Celsius, 46 to 86 degrees Fahrenheit, for up to 28 days; that it must be protected from light and kept in its carton; and that it must not be frozen and must not be used if it has been frozen.

That label sets the shipping envelope for the branded product. A brief excursion above refrigerator temperature during transit is tolerated. Freezing is not tolerated at all, which is the point operators most often get backwards. Over-icing a parcel, or letting a vial sit directly against a frozen gel pack, can freeze the product just as surely as a hot porch can cook it. The pack-out has to keep the product cold without ever letting it touch anything colder than the refrigerator range.

Compounded semaglutide and tirzepatide are a different case. They come from 503A compounding pharmacies as multi-dose vials, with a beyond-use date set by the pharmacy under USP compounding standards rather than a manufacturer's expiry, and their storage and excursion limits are whatever the pharmacy's own stability data supports. As of the FDA's April 1, 2026 update, neither drug is on the shortage list or the 503B bulks list, so compounded versions reach patients from 503A pharmacies on patient-specific prescriptions where state law and the clinical record allow. For those products the pharmacy's excursion policy is the document that governs, and a brand should have it in writing before the first shipment.

What a compliant shipment looks like

Compliance here belongs to the pharmacy, which is the licensee responsible for the medication until it reaches the patient's hands. The brand's interest is in knowing what good looks like well enough to specify it, audit it, and explain it to a patient. The USP's chapter on the storage and transportation of finished drug products, General Chapter 1079, is the reference pharmacies work to. Lyophilized peptides, the freeze-dried powders reconstituted before use, are the exception to most of the list below: they often ship at ambient temperature and go into the refrigerator once mixed, on the pharmacy's label.

• The pharmacy holds a license or nonresident pharmacy registration in the state the parcel is going to. Shipping into a state where it holds neither is unlawful regardless of how cold the box is.
• The insulated shipper and refrigerant have been qualified for the transit time and the season. Summer and winter pack-outs differ, and a pharmacy shipping the same configuration in January and July has not qualified either.
• There is a physical barrier between the product and the refrigerant so the vial never touches a frozen pack, and the refrigerant is conditioned to the right temperature before packing rather than taken straight from a freezer.
• A temperature indicator or logger rides with higher-value shipments, or with every shipment for a period after a pack-out change, so a warm-arrival claim can be checked against data instead of memory.
• The label carries the patient's name, the drug and strength, the beyond-use date, the storage instruction, the pharmacy's contact details and the state license number, and the outer carton says to refrigerate on arrival without saying what is inside.
• A patient insert explains what a normal arrival looks like, what a suspect one looks like, and exactly what to do and whom to contact in the second case.
• Transit is overnight or, at most, two days, with no planned weekend or holiday dwell, and the shipment is tracked from pharmacy scan to delivery scan with proof of delivery captured.

Carrier choice and cutoff design

Carriers are chosen for transit certainty rather than for price. A priority overnight service with a morning delivery window is the default for hot zones and for any address with a history of missed deliveries; a two-day service is acceptable where the pack-out is qualified for it and the route avoids a weekend. Saturday delivery is bought only where the carrier actually offers it at the destination, and Sunday and holiday delivery are treated as unavailable. Post office boxes are excluded at checkout, and the address is validated before the order reaches the pharmacy, since a bad apartment number is the cheapest failure to prevent.

Cutoffs are where operations and pharmacy meet. The pharmacy has a daily pickup time, and a prescription has to be received, verified, filled and packed before it. A refill approved late on a Thursday can miss Thursday's pickup, ship Friday, and, on a two-day service, sit in a depot across the weekend, which is the classic failed parcel. The fix is calendar design rather than heroics: renewal reviews are scheduled so that the provider's approval lands at least several business days before the patient's next dose date, the brand's system knows the pharmacy's cutoff and the carrier's weekend rules, and anything that cannot ship by Thursday on a two-day service waits for Monday on an overnight one.

Signature requirements are a real trade-off. Requiring one protects the parcel from a hot porch and creates a missed delivery for every patient who is at work. Most brands settle on no signature, hold-at-location for patients who ask, and weather holds during which the pharmacy pauses shipments to regions under extreme heat or storms and the brand's system tells the patient why the parcel has not moved.

Failure modes and who pays

A cold-chain failure is one of a short list of things, and each has a natural owner.

• Carrier delay past the pack-out's qualified duration: the pharmacy claims against the carrier where a guaranteed service was bought, and replaces the medication.
• Wrong address: where the patient typed it wrong, the cost sits with the patient or is absorbed by the brand as goodwill; where the pharmacy or carrier mislabeled or misdelivered, it sits with them.
• On-time delivery to a porch in heat, discovered hours later: contested by nature, and the agreement should say who absorbs it, because neither side will volunteer.
• Frozen product from refrigerant contact, or a pack-out that failed on a normal transit: the pharmacy's, without argument.
• Pharmacy error, such as the wrong strength, a missing supply or a mislabeled vial: the pharmacy's.
• A warm-arrival claim with no indicator and no photograph: the agreement needs an evidence standard and a default, because these are the majority of claims and the ones that sour a relationship.
• Patient not home, parcel returned to sender: nobody's fault and everybody's cost, and the agreement has to say who bears it.

Medication that has left the pharmacy generally cannot be returned to stock and resold, so every failed parcel is a full loss of product plus a second shipping charge. The brand's economic interest lies in a replacement rule that sends the second parcel out fast, before fault is settled, and squares the money afterward. A member who waits four days for a replacement while two companies argue over a gel pack is a member who is gone by the next renewal.

Pricing structure changes the arithmetic. Where the medication passes through at the pharmacy's own price, as it does under a zero-markup arrangement, a replacement costs exactly what the vial cost and no more, and the brand can afford a generous replacement policy without giving away margin it never had. Where a markup sits on the medication, every replacement is priced at the marked-up figure in someone's ledger, and the argument over fault becomes an argument over that margin. Tessic Health runs cold-chain home delivery on every plan through its wholesale pharmacy network at 0 percent medication markup, which is the arrangement that makes a replace-first policy affordable.

Talking to patients about delivery

Most warm-arrival claims are avoidable with three messages. Before the parcel ships, the patient hears the expected ship date, the carrier, what the box will look like, and that it goes into the refrigerator on arrival. When it ships, the patient gets the tracking link and the delivery window. When it is delivered, the patient is asked to check the parcel the same day and told, in one sentence, what to do if the gel packs are warm or the vial looks wrong: photograph the contents and the packs, do not use the medication, and contact support through the named channel.

Text messages are the natural channel and carry legal weight. The Telephone Consumer Protection Act allows statutory damages of $500 to $1,500 per message, and its implementing rule at 47 CFR 64.1200 requires prior express written consent for marketing texts. Shipping notifications are transactional rather than marketing, but the consent should be collected at checkout in a form that covers both, so that a shipping message with a promotion attached is covered too.

What the brand never tells patients is anything clinical. A missed dose because of a late parcel raises a question about timing the next injection, and that question belongs to the prescriber, so the support workflow routes it to a provider message rather than answering it from a script.

What to write into the pharmacy agreement

Most pharmacy agreements presented to a new brand say a great deal about pricing and almost nothing about a failed shipment. The clauses below are the ones that decide who pays and how fast the patient gets a second parcel, and they are cheap to negotiate before volume and expensive after.

• The pack-out specification, the transit durations and seasons it is qualified for, and an obligation to notify the brand before it changes.
• The carrier services the pharmacy will use by destination and season, the daily pickup cutoff, and the weekend and holiday rules.
• A weather-hold policy, with notice to the brand the same day so patients can be told.
• A replace-first commitment: a replacement ships within one business day of a reported failure, with fault settled afterward under the allocation table.
• The allocation table itself, covering each failure mode above, and the evidence standard for a warm-arrival claim, including whether an indicator or a photograph is required and what happens when neither exists.
• A minimum remaining beyond-use period on arrival, so a patient does not receive a vial with a week left on it.
• Nonresident pharmacy licensure in every state the brand serves, with a list the pharmacy keeps current and a duty to say when a state is lost.
• Complaint and recall handling, with the brand notified of any complaint that names its patients.
• Data: tracking events and delivery scans pushed into the brand's system in near real time, and a business associate agreement covering the patient information the pharmacy holds.
• Monthly reporting of failed shipments by cause, so the brand can see whether a pattern is the carrier, the pack-out, a region, or a checkout form that lets bad addresses through.

A pharmacy that resists the reporting clause has usually never measured its own failure rate. The weight loss and peptide launch pages describe how the pharmacy relationship is set up when it comes as part of the clinic rather than as a contract the brand negotiates alone.

The pharmacy sees one failed parcel. The brand sees a member whose next renewal is in question.

Questions operators ask

Can compounded semaglutide ship at room temperature? Only if the pharmacy's stability data says so for its preparation and for the transit time in question, and the pharmacy is willing to put that in the agreement. The approved product's label permits a limited excursion before first use; a compounded vial gets whatever tolerance its own pharmacy has established, and no more.

Does the pharmacy really need a license in every state? Yes. A pharmacy shipping prescription medication to a patient in another state needs that state's nonresident pharmacy license or registration, and a brand that expands into a new state before its pharmacy is licensed there has created the problem, not the pharmacy.

What happens when a patient reports a warm parcel and there is no indicator? Replace, log it, and look for the pattern. A single unverifiable claim is the cost of doing business. Three from the same ZIP code in a month is a carrier problem, and a run of them after a pack-out change is a pharmacy problem.

Are peptides handled the same way? Reconstituted peptides and any peptide supplied in solution ship cold like a GLP-1; lyophilized ones usually do not. The pharmacy's label decides, and the brand's patient insert has to match the label for that product rather than reuse the GLP-1 wording. The pharmacy owns the medication until it is delivered; the brand owns the member's opinion of what happened, and the contract should reflect that division.